Codexis Inc (CDXS) 3.80 $CDXS
Global Biocatalysis & Biocatalysts Market Report 2015-2019 with Novozymes, DuPont & DSM Featuring as the Most Active Players
M2 - Wed Mar 11, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxtvw4/biocatalysis_and) has announced the addition of the "Biocatalysis & Biocatalysts Market By Type (Hydrolases, Oxidoreductases, Transferases, And Others), Application (Food & Beverages, Cleaning Agents, Agriculture & Feed, Biofuel Production, Biopharmaceuticals, And Others), and Geography - Forecast to 2019 " report to their offering. The biocatalysts market was estimated around 81 kilo tons in 2013, with the high share of around 70% held by North America and Europe together. The global biocatalysts market by volume is projected to grow at a CAGR of 5.5% from 2014 to 2019. The high growth is forecasted to be in the RoW due to rise of end industries such as biofuel production, agriculture & feed, food and beverages in the region. Europe is estimated to have the second highest growth around 6.71% from 2014 to 2019. Advancements in the biocatalysis process have led to increased penetration of biocatalysts in different applications. Biofuel and detergent industries have the largest application of biocatalysts. Food & beverages, agriculture & feed, biopharmaceuticals are the other significant applications. Small applications include life science applications, textile, leather, pulp & paper, and flavor & fragrances. Biofuel and biopharmaceuticals applications are predicted to show the highest growth rate in the next five years. Hydrolases, transferases, and oxidoreductases are the major types of biocatalysts. The other three segments of biocatalysts lyases, isomerases, and ligases are small part of the biocatalysts market currently. The biocatalysts market is anticipated to show a high growth rate in the coming years. The market is innovation driven and investments are expected for new biocatalysis process and enzyme development. There are large numbers of various sized players in the market but it is dominated by few big companies. Currently, the biocatalyst market is mainly concentrated in the North American and European region while RoW region, especially Latin America is expected to show high growth rate in future years. Advancement in biocatalysis process along with increasing penetration of biocatalysts in different applications is driving the growth of the global biocatalysts market. Novozymes (Denmark), DuPont (U.S.), DSM (Netherlands) are the important active players in the biocatalysts market. These companies showed the highest strategy adoptions amongst other players in the biocatalysts market from 2010 to 2014. These companies together hold around 70% share of the biocatalysts market. From 2010 to 2014, partnership, agreement, and collaboration was observed as the most important growth strategy adopted by the major biocatalysts, accounting for a share of more than 50% of the total strategies adopted by the players. The other companies AB Enzymes (Germany), Codexis Inc. (U.S.), and BASF (Germany) also contributed to the market activities in the global biocatalysts market during the above mentioned period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Biocatalysis And Biocatalysts Market, By Type 8 Biocatalysis And Biocatalysts Market, By Application 9 Regional Analysis 10 Competitive Landscape 11 Company Profiles - Ab Enzymes Gmbh - Amano Enzymes - Basf Se - Chr. Hansen - Codexis Inc. - Dyadic International - E.I. Dupont De Nemours & Co. - Novozymes A/S - Royal Dsm N.V. - Soufflet Group For more information visit http://www.researchandmarkets.com/research/fx...alysis_and
CDXS: 3.80 (unch)
Codexis (CDXS) in Focus: Stock Falls 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 7:31AM CDT
Codexis saw a big move last session, as the company’s shares fell by over 7% on the day.
CDXS: 3.80 (unch), ABGB: 17.21 (+0.66)
Codexis' (CDXS) CEO John Nicols on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 7:16PM CST
CDXS: 3.80 (unch)
Codexis posts 4Q profit
Automated Insights - Tue Mar 03, 4:13PM CST
REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Tuesday reported fourth-quarter net income of $345,000, after reporting a loss in the same period a year earlier.
CDXS: 3.80 (unch)
Codexis (CDXS) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:25PM CST
CDXS: 3.80 (unch)
Codexis beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:14PM CST
CDXS: 3.80 (unch)
Codexis to Present at ROTH Conference
GlobeNewswire - Tue Mar 03, 7:00AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 27 Annual ROTH Conference on Tuesday, March 10, 2015, at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
CDXS: 3.80 (unch)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:35PM CST
AMBA: 72.39 (+3.14), BV: 5.90 (+0.01), AMRN: 2.52 (-0.03), AVAV: 26.85 (+0.41), BOBE: 46.64 (+0.28), TNET: 36.25 (+0.28), CECO: 5.59 (-0.25), VEEV: 27.28 (-0.65), REGI: 9.66 (+0.04), TIVO: 10.61 (+0.02), EGL: 34.37 (+1.51), ZLTQ: 34.35 (+0.77), LRE: 6.51 (+0.12), GERN: 3.98 (-0.15), ASNA: 14.07 (+0.11), CDXS: 3.80 (unch), SWHC: 13.53 (+0.10), ABM: 32.23 (+0.52)
Phenylketonuria (PKU) Therapeutics Pipeline Review 2015 - Analysis of 5 Companies & 6 Drug Profiles
M2 - Mon Mar 02, 6:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz4mm7/phenylketonuria) has announced the addition of the "Phenylketonuria (PKU) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Phenylketonuria (PKU), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Phenylketonuria (PKU) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Phenylketonuria (PKU) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Phenylketonuria (PKU) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - BioMarin Pharmaceutical Inc. - Codexis, Inc. - Erytech Pharma SA - Promethera Biosciences S.A. - SOM Innovation Biotech SL Drug Profiles - BMN-165 - Cell therapy for Phenylketonuria - HepaStem - Recombinant Enzyme to Replace Phenylalanine Hydroxylase for Phenyketonuria - sapropterin dihydrochloride - SOM-7400 For more information visit http://www.researchandmarkets.com/research/rz...lketonuria
BMRN: 125.17 (-2.32), CDXS: 3.80 (unch)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.10 (-0.41), CASM: 1.38 (+0.10), AMRN: 2.52 (-0.03), XON: 46.11 (-1.26), OSIR: 17.59 (-0.89), CPIX: 6.78 (-0.15), AMED: 26.74 (-0.25), CTIC: 1.93 (unch), INSY: 60.02 (-0.82), ECYT: 5.96 (-0.06), CMRX: 40.61 (-1.50), KYTH: 48.22 (+0.21), TRIB: 19.39 (+0.45), GALE: 1.46 (-0.03), ARNA: 4.80 (-0.21), XLRN: 41.82 (-0.62), ACRX: 4.15 (-0.09), ENDP: 92.37 (+0.89), DPLO: 27.89 (+0.81), SLXP: 172.80 (+0.26), PPHM: 1.49 (-0.04), MYL: 63.06 (-0.88), CBPO: 87.55 (-0.10), RGEN: 32.32 (-1.09), HALO: 14.63 (-1.43), ALIM: 5.12 (+0.08), ACHN: 11.06 (-0.36), GERN: 3.98 (-0.15), DARA: 0.82 (unch), SCMP: 17.89 (-0.67), ICPT: 290.98 (+2.47), CDXS: 3.80 (unch), PCRX: 97.64 (-0.08), PBYI: 234.00 (-15.71), FOLD: 11.61 (-0.85)
Numerous Catalysts For Codexis
Brandon Vara - Seeking Alpha - Tue Feb 17, 8:24AM CST
Codexis, Inc. (NASDAQ: CDXS ) is a microcap biotechnology company ($140M) with roughly 125 employees - a number that has been growing pretty steadily since its launch in 2002. The company has arguably been under the radar the past couple of years due...
MRK: 58.58 (+0.37), CDXS: 3.80 (unch), AMGN: 170.10 (+0.99), GSK: 48.81 (+0.60)
Codexis to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:27PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). The conference is being held at the Waldorf Astoria in New York City.
CDXS: 3.80 (unch)
Codexis (CDXS) Jumps: Stock Adds 8.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:11AM CST
Codexis, Inc. (CDXS) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
CDXS: 3.80 (unch), ABGB: 17.21 (+0.66)
Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration
GlobeNewswire - Wed Dec 03, 5:38PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. As a result, phenylalanine accumulates in high levels in the brain causing serious neurological problems, including intellectual disability, seizures and cognitive and behavioral problems. Phenylalanine is found in many foods, including meat, dairy products, fish, poultry and many fruits and vegetables.
CDXS: 3.80 (unch)
Global Synthetic Biology Market 2013-2020 - Opportunities and Forecasts for the $38 Billion Market
M2 - Thu Nov 27, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/g34xgv/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020) Key factors fueling the growth of this market include assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing. Bio-safety & bio-security and ethical issues are key restraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. However, as far as the market dynamics are considered, the bottom line is that the overall impact of these factors would be highly positive. Global synthetic biology market is segmented based on product, technology, application, and geography. Synthetic biology product market is further segmented into enabling products, enabled products and core products. Enabling product is the fastest growing segment in the product market due to ongoing researches that may bring-innovative ideas for application of synthetic biology in new fields. Thus, the need for enabling products, during R&D activities and in the development of enabled products, would rise. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market By Product Chapter 5 Global Synthetic Biology Market By Technologies Chapter 6 Global Synthetic Biology Market By Application Chapter 7 Synthetic Biology Market By Geography Chapter 8 Company Profiles - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/g3..._synthetic
CDXS: 3.80 (unch)
Codexis to Present at the LD Micro Main Event VII Conference on December 4
GlobeNewswire - Tue Nov 25, 7:07AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will provide a corporate update at the LD Micro Main Event VII Conference, being held December 2-4, 2014 at The Luxe Hotel in Los Angeles, California.
CDXS: 3.80 (unch)
Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
at The Street - Fri Nov 21, 1:45PM CST
Stocks with insider trader activity include ITG, CDXS and ARQL
ITG: 28.25 (+0.10), ARQL: 2.24 (-0.14), CDXS: 3.80 (unch)
Codexis misses by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:09PM CST
CDXS: 3.80 (unch)
Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Tue Nov 04, 3:03PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced financial results for the third quarter and nine months ended September 30, 2014.
CDXS: 3.80 (unch)
Global Biocatalysis & Biocatalysts Market Report 2015-2019 with Novozymes, DuPont & DSM Featuring as the Most Active Players
M2 - Wed Mar 11, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxtvw4/biocatalysis_and) has announced the addition of the "Biocatalysis & Biocatalysts Market By Type (Hydrolases, Oxidoreductases, Transferases, And Others), Application (Food & Beverages, Cleaning Agents, Agriculture & Feed, Biofuel Production, Biopharmaceuticals, And Others), and Geography - Forecast to 2019 " report to their offering. The biocatalysts market was estimated around 81 kilo tons in 2013, with the high share of around 70% held by North America and Europe together. The global biocatalysts market by volume is projected to grow at a CAGR of 5.5% from 2014 to 2019. The high growth is forecasted to be in the RoW due to rise of end industries such as biofuel production, agriculture & feed, food and beverages in the region. Europe is estimated to have the second highest growth around 6.71% from 2014 to 2019. Advancements in the biocatalysis process have led to increased penetration of biocatalysts in different applications. Biofuel and detergent industries have the largest application of biocatalysts. Food & beverages, agriculture & feed, biopharmaceuticals are the other significant applications. Small applications include life science applications, textile, leather, pulp & paper, and flavor & fragrances. Biofuel and biopharmaceuticals applications are predicted to show the highest growth rate in the next five years. Hydrolases, transferases, and oxidoreductases are the major types of biocatalysts. The other three segments of biocatalysts lyases, isomerases, and ligases are small part of the biocatalysts market currently. The biocatalysts market is anticipated to show a high growth rate in the coming years. The market is innovation driven and investments are expected for new biocatalysis process and enzyme development. There are large numbers of various sized players in the market but it is dominated by few big companies. Currently, the biocatalyst market is mainly concentrated in the North American and European region while RoW region, especially Latin America is expected to show high growth rate in future years. Advancement in biocatalysis process along with increasing penetration of biocatalysts in different applications is driving the growth of the global biocatalysts market. Novozymes (Denmark), DuPont (U.S.), DSM (Netherlands) are the important active players in the biocatalysts market. These companies showed the highest strategy adoptions amongst other players in the biocatalysts market from 2010 to 2014. These companies together hold around 70% share of the biocatalysts market. From 2010 to 2014, partnership, agreement, and collaboration was observed as the most important growth strategy adopted by the major biocatalysts, accounting for a share of more than 50% of the total strategies adopted by the players. The other companies AB Enzymes (Germany), Codexis Inc. (U.S.), and BASF (Germany) also contributed to the market activities in the global biocatalysts market during the above mentioned period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Biocatalysis And Biocatalysts Market, By Type 8 Biocatalysis And Biocatalysts Market, By Application 9 Regional Analysis 10 Competitive Landscape 11 Company Profiles - Ab Enzymes Gmbh - Amano Enzymes - Basf Se - Chr. Hansen - Codexis Inc. - Dyadic International - E.I. Dupont De Nemours & Co. - Novozymes A/S - Royal Dsm N.V. - Soufflet Group For more information visit http://www.researchandmarkets.com/research/fx...alysis_and
CDXS: 3.80 (unch)
Codexis (CDXS) in Focus: Stock Falls 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 7:31AM CDT
Codexis saw a big move last session, as the company’s shares fell by over 7% on the day.
CDXS: 3.80 (unch), ABGB: 17.21 (+0.66)
Codexis' (CDXS) CEO John Nicols on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 7:16PM CST
CDXS: 3.80 (unch)
Codexis posts 4Q profit
Automated Insights - Tue Mar 03, 4:13PM CST
REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Tuesday reported fourth-quarter net income of $345,000, after reporting a loss in the same period a year earlier.
CDXS: 3.80 (unch)
Codexis (CDXS) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:25PM CST
CDXS: 3.80 (unch)
Codexis beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:14PM CST
CDXS: 3.80 (unch)
Codexis to Present at ROTH Conference
GlobeNewswire - Tue Mar 03, 7:00AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 27 Annual ROTH Conference on Tuesday, March 10, 2015, at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
CDXS: 3.80 (unch)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:35PM CST
AMBA: 72.39 (+3.14), BV: 5.90 (+0.01), AMRN: 2.52 (-0.03), AVAV: 26.85 (+0.41), BOBE: 46.64 (+0.28), TNET: 36.25 (+0.28), CECO: 5.59 (-0.25), VEEV: 27.28 (-0.65), REGI: 9.66 (+0.04), TIVO: 10.61 (+0.02), EGL: 34.37 (+1.51), ZLTQ: 34.35 (+0.77), LRE: 6.51 (+0.12), GERN: 3.98 (-0.15), ASNA: 14.07 (+0.11), CDXS: 3.80 (unch), SWHC: 13.53 (+0.10), ABM: 32.23 (+0.52)
Phenylketonuria (PKU) Therapeutics Pipeline Review 2015 - Analysis of 5 Companies & 6 Drug Profiles
M2 - Mon Mar 02, 6:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz4mm7/phenylketonuria) has announced the addition of the "Phenylketonuria (PKU) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Phenylketonuria (PKU), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Phenylketonuria (PKU) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Phenylketonuria (PKU) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Phenylketonuria (PKU) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - BioMarin Pharmaceutical Inc. - Codexis, Inc. - Erytech Pharma SA - Promethera Biosciences S.A. - SOM Innovation Biotech SL Drug Profiles - BMN-165 - Cell therapy for Phenylketonuria - HepaStem - Recombinant Enzyme to Replace Phenylalanine Hydroxylase for Phenyketonuria - sapropterin dihydrochloride - SOM-7400 For more information visit http://www.researchandmarkets.com/research/rz...lketonuria
BMRN: 125.17 (-2.32), CDXS: 3.80 (unch)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.10 (-0.41), CASM: 1.38 (+0.10), AMRN: 2.52 (-0.03), XON: 46.11 (-1.26), OSIR: 17.59 (-0.89), CPIX: 6.78 (-0.15), AMED: 26.74 (-0.25), CTIC: 1.93 (unch), INSY: 60.02 (-0.82), ECYT: 5.96 (-0.06), CMRX: 40.61 (-1.50), KYTH: 48.22 (+0.21), TRIB: 19.39 (+0.45), GALE: 1.46 (-0.03), ARNA: 4.80 (-0.21), XLRN: 41.82 (-0.62), ACRX: 4.15 (-0.09), ENDP: 92.37 (+0.89), DPLO: 27.89 (+0.81), SLXP: 172.80 (+0.26), PPHM: 1.49 (-0.04), MYL: 63.06 (-0.88), CBPO: 87.55 (-0.10), RGEN: 32.32 (-1.09), HALO: 14.63 (-1.43), ALIM: 5.12 (+0.08), ACHN: 11.06 (-0.36), GERN: 3.98 (-0.15), DARA: 0.82 (unch), SCMP: 17.89 (-0.67), ICPT: 290.98 (+2.47), CDXS: 3.80 (unch), PCRX: 97.64 (-0.08), PBYI: 234.00 (-15.71), FOLD: 11.61 (-0.85)
Numerous Catalysts For Codexis
Brandon Vara - Seeking Alpha - Tue Feb 17, 8:24AM CST
Codexis, Inc. (NASDAQ: CDXS ) is a microcap biotechnology company ($140M) with roughly 125 employees - a number that has been growing pretty steadily since its launch in 2002. The company has arguably been under the radar the past couple of years due...
MRK: 58.58 (+0.37), CDXS: 3.80 (unch), AMGN: 170.10 (+0.99), GSK: 48.81 (+0.60)
Codexis to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:27PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). The conference is being held at the Waldorf Astoria in New York City.
CDXS: 3.80 (unch)
Codexis (CDXS) Jumps: Stock Adds 8.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:11AM CST
Codexis, Inc. (CDXS) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
CDXS: 3.80 (unch), ABGB: 17.21 (+0.66)
Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration
GlobeNewswire - Wed Dec 03, 5:38PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. As a result, phenylalanine accumulates in high levels in the brain causing serious neurological problems, including intellectual disability, seizures and cognitive and behavioral problems. Phenylalanine is found in many foods, including meat, dairy products, fish, poultry and many fruits and vegetables.
CDXS: 3.80 (unch)
Global Synthetic Biology Market 2013-2020 - Opportunities and Forecasts for the $38 Billion Market
M2 - Thu Nov 27, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/g34xgv/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020) Key factors fueling the growth of this market include assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing. Bio-safety & bio-security and ethical issues are key restraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. However, as far as the market dynamics are considered, the bottom line is that the overall impact of these factors would be highly positive. Global synthetic biology market is segmented based on product, technology, application, and geography. Synthetic biology product market is further segmented into enabling products, enabled products and core products. Enabling product is the fastest growing segment in the product market due to ongoing researches that may bring-innovative ideas for application of synthetic biology in new fields. Thus, the need for enabling products, during R&D activities and in the development of enabled products, would rise. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market By Product Chapter 5 Global Synthetic Biology Market By Technologies Chapter 6 Global Synthetic Biology Market By Application Chapter 7 Synthetic Biology Market By Geography Chapter 8 Company Profiles - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/g3..._synthetic
CDXS: 3.80 (unch)
Codexis to Present at the LD Micro Main Event VII Conference on December 4
GlobeNewswire - Tue Nov 25, 7:07AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will provide a corporate update at the LD Micro Main Event VII Conference, being held December 2-4, 2014 at The Luxe Hotel in Los Angeles, California.
CDXS: 3.80 (unch)
Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
at The Street - Fri Nov 21, 1:45PM CST
Stocks with insider trader activity include ITG, CDXS and ARQL
ITG: 28.25 (+0.10), ARQL: 2.24 (-0.14), CDXS: 3.80 (unch)
Codexis misses by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:09PM CST
CDXS: 3.80 (unch)
Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Tue Nov 04, 3:03PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced financial results for the third quarter and nine months ended September 30, 2014.
CDXS: 3.80 (unch)
